Association Between Biomarkers and Kidney Function Decline in Pulmonary Hypertension
1 other identifier
observational
350
1 country
1
Brief Summary
The objective of this study is to examine the association between urinary and plasma biomarkers and change in estimated glomerular filtration rate (eGFR) among patients with pulmonary hypertension (PH).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2024
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 7, 2024
CompletedFirst Posted
Study publicly available on registry
May 10, 2024
CompletedStudy Start
First participant enrolled
May 31, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2027
October 6, 2025
September 1, 2025
2.6 years
May 7, 2024
September 30, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Major adverse kidney events
Number of patients experiencing ≥q of the individual outcomes of the composite outcome of eGFR decline ≥25%, initiation of dialysis, or all-cause mortality
Baseline to 12 months
Secondary Outcomes (3)
Initiation of dialysis
Baseline to 12 months
All-cause mortality
Baseline to 12 months
Kidney function decline
12 months
Other Outcomes (1)
Worsening PH
Baseline to 12 months
Study Arms (2)
Pulmonary hypertension
Patients with diagnosed PH by right heart catheterization with or without PH-specific treatment
No pulmonary hypertension
Patients in whom PH was excluded by right heart catheterization
Interventions
No intervention is planned as part of the study
Eligibility Criteria
Inpatients admitted at University Hospital Giessen and Marburg, Campus Giessen with suspected or pre-diagnosed PH undergoing RHC
You may qualify if:
- Inpatients aged ≥18 years
- Undergoing right heart catheterization (RHC)
You may not qualify if:
- Active tumor disease requiring targeted therapy
- inflammatory or autoimmune disease with renal involvement requiring systemic immunosuppressive treatment
- unexplained kidney function decline, defined as serum creatinine increase ≥0.5 mg/dL from baseline within the prior 7 days before RHC
- Chronic kidney disease with eGFR \<20 ml/min/1.73 m2
- non-kidney failure requiring extracorporeal or peritoneal ultrafiltration for diuretic-resistant volume overload
- if they had received non-steroidal anti-inflammatory drugs or intravenous contrast within 72 hours before RHC
- prediagnosed glomerulonephritis
- polycystic kidney disease
- postrenal obstruction
- single kidney (functional or anatomical)
- solid organ transplantation
- anticipated life expectancy of \<12 months
- likelihood of receiving advanced therapy (mechanical circulatory assist device/lung or cardiac transplant)
- pregnancy or possibility of pregnancy in the next 12 months
- inability to cooperate with respiratory maneuvers during renal Doppler
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Giessenlead
- Icahn School of Medicine at Mount Sinaicollaborator
- University of Virginiacollaborator
Study Sites (1)
University Hospital Giessen and Marburg, Campus Giessen, Department of Internal Medicine II
Giessen, Hesse, 35392, Germany
Related Publications (2)
Husain-Syed F, DiFrancesco MF, Deo R, Barr RG, Scialla JJ, Bluemke DA, Kronmal RA, Lima JAC, Praestgaard A, Tracy RP, Shlipak M, Kawut SM, Kim JS. Associations between eGFR and albuminuria with right ventricular measures: the MESA-Right Ventricle study. Clin Kidney J. 2023 Apr 21;16(9):1508-1520. doi: 10.1093/ckj/sfad096. eCollection 2023 Sep.
PMID: 37664568BACKGROUNDChakinala MM, Coyne DW, Benza RL, Frost AE, McGoon MD, Hartline BK, Frantz RP, Selej M, Zhao C, Mink DR, Farber HW. Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. J Heart Lung Transplant. 2018 Jun;37(6):696-705. doi: 10.1016/j.healun.2017.10.028. Epub 2017 Nov 6.
PMID: 29174533RESULT
Biospecimen
Urine and blood samples.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Faeq Husain-Syed, MD
University of Giessen
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 7, 2024
First Posted
May 10, 2024
Study Start
May 31, 2024
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
July 1, 2027
Last Updated
October 6, 2025
Record last verified: 2025-09